Amgen Inc.

Climate Impact & Sustainability Data (2021)

Total Carbon Emissions:155,000 MT CO2Eq

Renewable Energy Share:79%

Total Energy Consumption:3,193,000 GJ

Water Consumption:2,238,000 CM

Waste Generated:10,289 MT

Achieved 79% renewable energy share in total electricity consumption (up from 41% in 2020)
Reduced carbon emissions by 36% from 2020
Exceeded goals for carbon, water, and waste reductions in 2021
Announced aspiration to achieve net-zero carbon emissions in operations by 2027, along with 40% reduction in water use and 75% reduction in waste disposed
Issued its first-ever green bond, raising $750 million to support environmental sustainability aspirations

Provided approximately $2.2 billion of Amgen medicines at no cost to uninsured or underinsured patients in the U.S.
Provided 900,000 daily doses of medicines at no cost in over 20 low- and middle-income countries
Amgen Foundation supported science education programs reaching over 27 million students and educators worldwide
Amgen Foundation provided $3 million to support racial and social justice initiatives
Continued efforts to improve workforce diversity
Provided additional mental health resources to support employees
Increased ERG membership by 41%
Launched a mentoring program for high-performing women of color

Diverse and independent Board of Directors
Included ESG performance in Company goals under annual incentive compensation plan
Zero Class 1 or 2 product recalls
100% of employees trained on the Code of Conduct

Short-term Goals:

Achieve carbon neutrality for Amgen-owned and operated facilities and operations by 2027
Reduce water consumption by 40% from a 2019 baseline by 2027
Reduce waste disposed by 75% from a 2019 baseline by 2027
Convert 30% of sales fleet vehicles to electric vehicles by 2027

COVID-19 pandemic impacting employee health and safety, clinical trials, and supply chain
Underrepresentation of racial and ethnic minority patients in clinical trials
Barriers to access to medicines and healthcare
Climate change and its impact on lung health
Cybersecurity threats

Implemented additional safety measures at manufacturing and research sites
Provided additional mental health resources and flexible work arrangements
Supported clinical sites and ensured continued supply of medicines
Developed a dedicated COVID-19 vaccine internal webpage and education materials
Implemented a vaccination requirement for U.S. staff
Invested in programs to increase diversity and representation in clinical trials
Partnered with organizations to expand access to medicines and healthcare
Sponsored reports on the impact of COVID-19 on cancer diagnosis in Europe
Collaborated with organizations to address climate change and lung health
Implemented a robust enterprise-wide cybersecurity program

Supplier Audits: ~70% of total supplier spend

Frameworks Used: Biopharma Investor ESG Communications Guidance, SASB, TCFD, UN Global Compact, UN Sustainable Development Goals